Accuray Reports Fourth Quarter and Fiscal 2022 Financial Results
Accuray Incorporated (NASDAQ: ARAY) reported FY22 revenue growth of 8.5%, totaling $429.9 million. The fourth quarter ended June 30, 2022, saw gross orders of $88.3 million and net revenue of $110.0 million. Despite a GAAP net loss of $3.5 million for Q4, there was an improved loss compared to last year. Adjusted EBITDA for FY22 was $22.8 million. The company’s ClearRT™ imaging technology won a prestigious award. However, the ending backlog decreased by 8.6% to $563.7 million.
- 8.5% revenue growth in FY22.
- Gross orders totaled $332.3 million for FY22, an increase of 1.9%.
- Established a new award for ClearRT™ Helical Fan-Beam kVCT Imaging.
- GAAP net loss of $5.3 million for FY22, though improved from prior year.
- Adjusted EBITDA decreased to $22.8 million from $38.0 million last year.
- Ending backlog reduced by 8.6% to $563.7 million due to delayed installations.
SUNNYVALE, Calif., Aug. 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2022 ended June 30, 2022.
Q4 Fiscal 2022 and Recent Operating Highlights
- Gross orders of
$88.3 million - Net revenue of
$110.0 million - GAAP net loss of
$3.5 million . Adjusted EBITDA of$5.2 million - Accuray ClearRT™ Helical Fan-Beam kVCT Imaging wins "Best New Technology Solution for Oncology" MedTech Breakthrough Award
Fiscal Year 2022 Highlights
- Gross orders of
$332.3 million and ending backlog of$563.7 million - Net revenue of
$429.9 million , an increase of8.5% from fiscal 2021 - GAAP net loss of
$5.3 million improved from GAAP net loss of$6.3 million in the prior year. Adjusted EBITDA of$22.8 million as compared to adjusted EBITDA of$38.0 million in the prior year - Accuray CyberKnife® System real world data and clinical studies presented at the International Stereotactic Radiosurgery Society congress reinforce benefits experienced by people with neurological indications treated over the last two decades
"The Accuray team delivered a solid fourth quarter beating consensus despite supply chain disruption and impacts from the COVID-19 lock downs in China. For the year, we delivered historic revenue levels demonstrating strong customer adoption of our latest product innovation. We continue to build a stronger business and invest in areas that are expected to deliver value to our customers to advance patient care," said Suzanne Winter, President and Chief Executive Officer.
Gross orders totaled
Total revenue was
Total gross profit for the fourth quarter of fiscal 2022 was
Operating expenses were
Net loss was
Adjusted EBITDA for the fourth quarter of fiscal 2022 was
Cash, cash equivalents, and short-term restricted cash were
For the fiscal year ended June 30, 2022, gross orders totaled
Total revenue was
Total gross profit for the year ended June 30, 2022 was
Operating expenses were
Net loss was
Prior fiscal year net loss included a one-time charge interest expense of
Adjusted EBITDA for the fiscal year ended June 30, 2022 was
Accuray's financial guidance is based on current expectations. The following statements are forward-looking and actual results could differ materially depending on market and economic conditions, the impact of the COVID-19 pandemic, supply chain disruption, and the factors set forth under "Safe Harbor Statement" below.
The Company is introducing guidance for fiscal year 2023 as follows:
- Total revenue is expected in the range of
$447 million to$455 million , representing a year-over-year growth range of4% to6% . - Adjusted EBITDA is expected in the range of
$26 million to$30 million .
"While supply chain constraints, foreign exchange headwinds, and COVID-19 related lock downs in China are expected to create near term pressure, we believe our new product introductions will serve as catalysts for growth in FY23. We remain focused on margin expansion plans and investments in research and development to drive innovation and create shareholder value in the long term," said Ali Pervaiz, Chief Financial Officer.
Guidance for Adjusted EBITDA, a non-GAAP financial measures excludes depreciation and amortization, stock-based compensation expense, Enterprise Resource Planning (ERP) and ERP related expenditures, interest expense and provision for income taxes. For more information regarding the non-GAAP financial measures discussed in this press release, please see "Use of Non-GAAP Financial Measures" below.
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the fourth quarter of fiscal 2022 as well as recent corporate developments. Conference call dial-in information is as follows:
- U.S. callers: (833) 316-0563
- International callers: (412) 317-5747
Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray's website, www.accuray.com. There will be a slide presentation accompanying today's event which can also be accessed on the company's Investor Relations page at www.accuray.com.
In addition, a taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and will be available for seven days. The replay number is (877) 344-7529 (USA), or (412) 317-0088 (International), Conference ID: 4554339. An archived webcast will also be available on Accuray's website until Accuray announces its results for the first quarter of fiscal 2023.
Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, ERP and ERP related expenditures, depreciation, amortization and stock-based compensation ("adjusted EBITDA"). The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net income (loss) (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.
There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.
Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide.
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including expectations regarding total revenue and adjusted EBITDA; expectations regarding the effect of the COVID-19 pandemic, supply chain and logistics challenges on the company and the market in general; expectations regarding the company's commercial strategy and execution as well as long-term growth opportunities and catalysts; expectations regarding demand for the company's products, adoption of new products and the company's order growth; the company's innovation-driven growth strategy and its ability to continue to build a stronger business, deliver value to its customers and create shareholder value and return on investment in the long term; expectations regarding the company's China joint venture and other partnerships; expectations regarding the company's products and new product innovations and developments; expectations regarding the company's product portfolio and its ability to position the company for growth; the impact of the company's products on its customers and its business, and market adoption of such products, including with respect to the company's VOLO Ultra enhancement and Clear RT Helical kVCT Imaging upgrades as well as other strategic product innovations; expectations regarding the future of radiotherapy treatment and the company's addressable market; and the company's leadership position in radiation oncology innovation and technologies. These forward-looking statements involve risks and uncertainties. If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the COVID-19 pandemic on the operations of the company and those of its customers and suppliers; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products, including new product and software offerings; the company's ability to develop new products or enhance existing products to meet customers' needs and compete favorably in the market, the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to effectively manage its growth; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on April 29, 2022 and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Aman Patel, CFA | Beth Kaplan |
Investor Relations, ICR-Westwicke | Public Relations Director, Accuray |
+1 (443) 450-4191 | +1 (408) 789-4426 |
aman.patel@westwicke.com |
###
Financial Tables to Follow
Accuray Incorporated | ||||||||||||||||
Condensed Consolidated Statements of Operations | ||||||||||||||||
(in thousands, except per share data) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Net revenue: | ||||||||||||||||
Products | $ | 58,037 | $ | 56,145 | $ | 214,715 | $ | 176,647 | ||||||||
Services | 51,986 | 54,791 | 215,194 | 219,642 | ||||||||||||
Total net revenue | 110,023 | 110,936 | 429,909 | 396,289 | ||||||||||||
Cost of revenue: | ||||||||||||||||
Cost of products | 31,887 | 32,863 | 127,287 | 102,100 | ||||||||||||
Cost of services | 35,116 | 34,342 | 142,667 | 134,682 | ||||||||||||
Total cost of revenue | 67,003 | 67,205 | 269,954 | 236,782 | ||||||||||||
Gross profit | 43,020 | 43,731 | 159,955 | 159,507 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 14,569 | 15,357 | 57,752 | 52,729 | ||||||||||||
Selling and marketing | 14,362 | 13,007 | 49,664 | 42,820 | ||||||||||||
General and administrative | 12,041 | 11,225 | 44,391 | 41,723 | ||||||||||||
Total operating expenses | 40,972 | 39,589 | 151,807 | 137,272 | ||||||||||||
Income from operations | 2,048 | 4,142 | 8,148 | 22,235 | ||||||||||||
Income (loss) on equity investment, net | (533) | (149) | 241 | 872 | ||||||||||||
Other expense, net | (2,940) | (14,685) | (10,391) | (27,666) | ||||||||||||
Loss before provision for income taxes | (1,425) | (10,692) | (2,002) | (4,559) | ||||||||||||
Provision for income taxes | 2,027 | 400 | 3,345 | 1,752 | ||||||||||||
Net loss | $ | (3,452) | $ | (11,092) | $ | (5,347) | $ | (6,311) | ||||||||
Net loss per share - basic | $ | (0.04) | $ | (0.12) | $ | (0.06) | $ | (0.07) | ||||||||
Net loss per share - diluted | $ | (0.04) | $ | (0.12) | $ | (0.06) | $ | (0.07) | ||||||||
Weighted average common shares used in | ||||||||||||||||
Basic | 93,047 | 91,613 | 92,095 | 92,031 | ||||||||||||
Diluted | 93,047 | 91,613 | 92,095 | 92,031 | ||||||||||||
Accuray Incorporated | ||||||||
Condensed Consolidated Balance Sheets | ||||||||
(in thousands) | ||||||||
(Unaudited) | ||||||||
June 30, | June 30, | |||||||
2022 | 2021 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 88,737 | $ | 116,369 | ||||
Restricted cash | 204 | 560 | ||||||
Accounts receivable, net | 94,442 | 85,360 | ||||||
Inventories | 142,254 | 125,929 | ||||||
Prepaid expenses and other current assets | 23,794 | 21,547 | ||||||
Deferred cost of revenue | 1,459 | 3,008 | ||||||
Total current assets | 350,890 | 352,773 | ||||||
Property and equipment, net | 12,685 | 12,332 | ||||||
Investment in joint venture | 13,879 | 15,935 | ||||||
Operating lease right-of-use assets | 16,798 | 22,522 | ||||||
Goodwill | 57,840 | 57,960 | ||||||
Intangible assets, net | 250 | 435 | ||||||
Restricted cash | 1,213 | 1,272 | ||||||
Other assets | 19,294 | 16,869 | ||||||
Total assets | $ | 472,849 | $ | 480,098 | ||||
Liabilities and equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 31,337 | $ | 19,467 | ||||
Accrued compensation | 29,441 | 26,865 | ||||||
Operating lease liabilities, current | 8,567 | 8,169 | ||||||
Other accrued liabilities | 30,285 | 27,471 | ||||||
Customer advances | 25,290 | 24,937 | ||||||
Deferred revenue | 75,375 | 81,660 | ||||||
Short-term debt | 8,563 | 3,790 | ||||||
Total current liabilities | 208,858 | 192,359 | ||||||
Long-term other liabilities | 10,453 | 7,766 | ||||||
Deferred revenue | 3,748 | 23,685 | ||||||
Operating lease liabilities, non-current | 24,694 | 17,441 | ||||||
Long-term debt | 171,907 | 170,007 | ||||||
Total liabilities | 419,660 | 411,258 | ||||||
Equity: | ||||||||
Common stock | 94 | 91 | ||||||
Additional paid-in capital | 543,211 | 554,680 | ||||||
Accumulated other comprehensive income | 2,406 | 2,093 | ||||||
Accumulated deficit | (492,522) | (488,024) | ||||||
Total equity | 53,189 | 68,840 | ||||||
Total liabilities and equity | $ | 472,849 | $ | 480,098 | ||||
Accuray Incorporated | ||||||||||||||||
Summary of Orders and Backlog | ||||||||||||||||
(in thousands) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Gross Orders | $ | 88,342 | $ | 112,672 | $ | 332,268 | $ | 325,929 | ||||||||
Net Orders | 42,828 | 63,038 | 167,316 | 191,881 | ||||||||||||
Order Backlog | 563,684 | 616,399 | 563,684 | 616,399 | ||||||||||||
Accuray Incorporated | ||||||||||||||||
Reconciliation of GAAP Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, | ||||||||||||||||
Amortization, Stock-Based Compensation and Other (Adjusted EBITDA) | ||||||||||||||||
(in thousands) | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
GAAP net loss | $ | (3,452) | $ | (11,092) | $ | (5,347) | $ | (6,311) | ||||||||
Depreciation and amortization | 1,275 | 1,498 | 5,522 | 6,389 | ||||||||||||
Stock-based compensation | 2,694 | 2,236 | 10,600 | 9,332 | ||||||||||||
Interest expense, net | 2,028 | 3,734 | 8,109 | 16,877 | ||||||||||||
ERP and ERP related expenditures | 594 | — | 594 | — | ||||||||||||
One-time charge related to debt refinance and convertible | — | 9,948 | — | 9,948 | ||||||||||||
Provision for income taxes | 2,027 | 400 | 3,345 | 1,752 | ||||||||||||
Adjusted EBITDA | $ | 5,166 | $ | 6,724 | $ | 22,823 | $ | 37,987 | ||||||||
(a) | consists of depreciation, primarily on property and equipment as well as amortization of intangibles. |
(b) | consists primarily of interest expense associated with outstanding debt. |
Accuray Incorporated | ||||||||
Forward-Looking Guidance | ||||||||
Reconciliation of Projected Net Loss to Projected Adjusted Earnings Before Interest, Taxes, Depreciation, | ||||||||
(in thousands) | ||||||||
Twelve Months Ending | ||||||||
From | To | |||||||
GAAP net income (loss) | $ | (3,500) | $ | 500 | ||||
Depreciation and amortization (a) | 6,300 | 6,300 | ||||||
Stock-based compensation | 11,600 | 11,600 | ||||||
Interest expense, net (b) | 8,000 | 8,000 | ||||||
Provision for income taxes | 2,000 | 2,000 | ||||||
ERP and ERP related expenditures | 1,600 | 1,600 | ||||||
Adjusted EBITDA | $ | 26,000 | $ | 30,000 | ||||
(a) | consists of depreciation, primarily on property and equipment as well as amortization of intangibles. |
(b) | consists primarily of interest expense associated with outstanding debt. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-reports-fourth-quarter-and-fiscal-2022-financial-results-301603116.html
SOURCE Accuray Incorporated
FAQ
What are Accuray's financial results for Q4 FY2022?
What is the revenue growth for Accuray in FY2022?
What were Accuray's net losses for FY2022?
What is Accuray's ending backlog as of FY2022?
What is the adjusted EBITDA for Accuray in FY2022?
